Wolverine Trading’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Wolverine Trading’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,300	Closed	-$640K	–	6180
2022 Q1	$640K	Buy	+18,300	New	+$547K	﹤0.01%	2949
2021 Q4	–	Sell	-12,300	Closed	-$317K	–	7282
2021 Q3	$317K	Buy	12,300 +3,700	+43%	+$109K	﹤0.01%	4625
2021 Q2	$279K	Sell	8,600 -700	-8%	-$27.3K	﹤0.01%	4525
2021 Q1	$379K	Sell	9,300 -13,000	-58%	-$598K	﹤0.01%	4126
2020 Q4	$987K	Buy	22,300 +12,300	+123%	+$606K	﹤0.01%	2404
2020 Q3	$539K	Buy	+10,000	New	+$636K	﹤0.01%	2732
2020 Q2	–	Sell	-9,400	Closed	-$489K	–	5470
2020 Q1	$489K	Sell	9,400 -10,300	-52%	-$690K	﹤0.01%	2685
2019 Q4	$1.56M	Buy	19,700 +4,800	+32%	+$284K	﹤0.01%	2024
2019 Q3	$734K	Sell	14,900 -8,900	-37%	-$464K	﹤0.01%	2233
2019 Q2	$1.25M	Buy	23,800 +3,500	+17%	+$201K	﹤0.01%	1854
2019 Q1	$1.07M	Sell	20,300 -15,600	-43%	-$767K	﹤0.01%	2008
2018 Q4	$1.44M	Sell	35,900 -10,400	-22%	-$390K	﹤0.01%	1680
2018 Q3	$1.76M	Buy	+46,300	New	+$2.05M	﹤0.01%	1797

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Wolverine Trading's GBT Position: Q3 2021 in Review

Wolverine Trading sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 7,260 shares — an estimated $213K sold.

Wolverine Trading first reported a position in GBT in Q3 2018 and held it in 11 quarters. The position peaked at $1.44M in Q1 2020. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

Wolverine Trading reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
Wolverine Trading sold 7,260 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $213K.
Wolverine Trading first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 11 quarters.
Wolverine Trading's Global Blood Therapeutics, Inc. position peaked at $1.44M in Q1 2020.
187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.